COMP <GO>
MGRX vs NIVF // NET PROFIT MARGIN
Mangoceuticals Inc. (NASDAQ) VS. NewGenIvf Group Limited (Class A) (NASDAQ) • 15-METRIC TALLY: MGRX 1
— NIVF 5
▲ NET PROFIT MARGIN LEADER: NIVF
LAST: $0.25 (-1.47%) • MKT CAP: $5.7M
net-margins
-60.00%
LAST: $1.14 (-5.00%) • MKT CAP: $11.3M
net-margins
68.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MGRX VS. NIVF)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MGRX | NIVF | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.90% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -32.80% | -2.20 | NIVF | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -60.00% | 68.00% | -128.00 | NIVF | /net-margins <GO> |
| Revenue Growth (YoY) | -26.00% | -13.00% | -13.00 | NIVF | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 0.63 | -0.43 | NIVF | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.1 | 22.5 | +9.55 | MGRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.7M | $11.3M | -$5.6M | NIVF | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MGRX REV | NIVF REV | MGRX GROSS % | NIVF GROSS % | MGRX FCF | NIVF FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $456.0K | $4.7M | 54.9% | 20.2% | -$5.9M | -$11.1M |
| FY 2024 | $615.9K | $5.4M | 61.7% | 33.6% | -$4.9M | -$8.3M |
| FY 2023 | $731.5K | $5.1M | — | — | -$7.0M | -$1.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MGRX // BETA —
NIVF // BETA —